Latest Breaking News On - Oz adler - Page 6 : comparemela.com

SciSparc Granted European Patent for its Core Technology

The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that The European Patent Office has granted it a new patent

United statesOz adlerEuropean patent officeScisparc ltdExchange commissionCompany or scisparcChief executive officerTourette syndromeLooking statementsPrivate securities litigation reform actAnnual reportScisparc ltdThe companyTherapeutic effectsPharmaceutical companyEuropean application

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder

SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Oz adlerCompany or scisparcScisparc ltdExchange commissionNational autism research centerSoroka university medical centerSoroka university medicalAutism spectrum disorderAberrant behavior checklist communityClinical global impressions improvementChief executive officerTourette syndromeLooking statementsPrivate securities litigation reform actAnnual report

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOz adlerYale child study centerCompany or scisparcHannover medical schoolTel aviv sourasky medical centerYale school of medicineHannover medical school inIsraeli ministry of healthExchange commissionScisparc ltdInstitute for drugsClinical trialTourette syndromeYale schoolChief executive officer

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U S

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U S
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesScisparc palmitoylethanolamideOz adlerScisparc ltdExchange commissionTrademark officeCompany or scisparcClearmind medicine incTourette syndromeClearmind medicineUnited states patentChief executive officerLooking statementsPrivate securities litigation reform actAnnual report

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

“We hope the outcome of this trial will enable the Company to procced with commercialization process for SCI-210 in Israel TEL AVIV, Israel, July 14, 2023 SciSparc Ltd. , a specialty.

Magister landsheftYuval landsheftOz adlerNational autism research centerIsraeli medical cannabis agencySoroka university medical center ethics committeeIsraeli ministry of healthScisparc ltdExchange commissionCompany or scisparcIsraeli ministryChief executive officerAberrant behavior checklist communityClinical global impressions improvementTourette syndromeLooking statements